108 related articles for article (PubMed ID: 32199933)
1. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
Farhadfar N; Li Y; May WS; Adams CB
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):246-251. PubMed ID: 32199933
[TBL] [Abstract][Full Text] [Related]
2. A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
Tang H; Jia W; Jia S; Dong R; Gao S; Feng J; Dong H; Gu H; Zhang T; Yuan R; Liu X; Cheng L; Zhou S; Gao G
Am J Hematol; 2024 Jun; 99(6):1177-1179. PubMed ID: 38482543
[No Abstract] [Full Text] [Related]
3. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Pocock R; Farah N; Richardson SE; Mansour MR
Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of
Tari K; Nasimian A; Kazi JU; Abroun S
Int J Mol Cell Med; 2023; 12(3):229-241. PubMed ID: 38751657
[TBL] [Abstract][Full Text] [Related]
6. A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine.
Hu M; Li W; Li P; Tan J; Wang Y
Front Oncol; 2024; 14():1329279. PubMed ID: 38737911
[TBL] [Abstract][Full Text] [Related]
7. Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression.
Rinella SP; Bell HC; Hess NJ; Hoang NM; Nguyen TT; Turicek DP; Shi L; Rui L; LaBelle JL; Capitini CM
bioRxiv; 2024 May; ():. PubMed ID: 37333339
[TBL] [Abstract][Full Text] [Related]
8. SMACing down relapsed T-ALL.
Sawyer EM; Kraft AS
Blood; 2024 May; 143(21):2116-2117. PubMed ID: 38780917
[No Abstract] [Full Text] [Related]
9. Venetoclax use in a patient with ataxia telangiectasia and early T-cell precursor acute lymphoblastic leukemia.
Alqahtani S; Ramakrishnan R; E S; Wang SA; Nunez C; McCall D; Garcia MB; Roth ME; Cuglievan B; Gibson A
Pediatr Blood Cancer; 2024 Jun; ():e31123. PubMed ID: 38837565
[No Abstract] [Full Text] [Related]
10. MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
Zhang X; Zhong Y; Liu L; Suo S; Zhao S; Xiao F; Qin J; Tong H; Jin J; Yu W
Br J Haematol; 2024 Apr; ():. PubMed ID: 38685592
[No Abstract] [Full Text] [Related]
11. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia.
Zappone E; Cencini E; Defina M; Sicuranza A; Gozzetti A; Ciofini S; Raspadori D; Mecacci B; Bocchia M
Clin Case Rep; 2020 Oct; 8(10):2000-2002. PubMed ID: 33088538
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
Baig MU; Rytting M; Roth M; Morani AC; Nunez C; Lin P; Cuglievan B
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e991-e996. PubMed ID: 33480649
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia.
La Starza R; Cambò B; Pierini A; Bornhauser B; Montanaro A; Bourquin JP; Mecucci C; Roti G
JCO Precis Oncol; 2019; 3():. PubMed ID: 32923866
[No Abstract] [Full Text] [Related]
14. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
16. Precision medicine in acute lymphoblastic leukemia.
Pui CH
Front Med; 2020 Dec; 14(6):689-700. PubMed ID: 33074527
[TBL] [Abstract][Full Text] [Related]
17. Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease.
Curran E; O'Brien M
Semin Hematol; 2020 Jul; 57(3):157-163. PubMed ID: 33256906
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
Arora S; Vachhani P; Bachiashvili K; Jamy O
Leuk Lymphoma; 2021 Sep; 62(9):2292-2294. PubMed ID: 33691573
[No Abstract] [Full Text] [Related]
19. Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS).
Klocke H; Dong ZM; O'Brien C; Burwick N; Richard RE; Wu DY; Chauncey TR; Graf SA
Case Rep Hematol; 2020; 2020():8811673. PubMed ID: 33101740
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
